Taking Care of Veterans With Opioid Use Disorders: Early Identification and Comprehensive Treatment Services
Approximately ___ of persons with opioid use disorder never receive treatment for this condition.
D. Nearly 80% of persons with opioid use disorder (OUD) never receive treatment for this condition. For more information on OUD in veterans, click the “Start” button on this page. (Substance Abuse and Mental Health Services Administration. Medication-assisted treatment of opioid use disorder. Pocket guide. 2016.)
Thomas Kosten, MD
JH Waggoner Chair and Professor of Psychiatry
Co-Director, Dan L. Duncan Institute for Clinical and Translational Research (ICTR)
Baylor College of Medicine
Michael E. DeBakey VA Medical Center
Julie Blum, PhD
Senior Clinical Content Manager
Laura Rafferty, ELS
Kathryn Schaefer, MSN, RN
Lead Nurse Planner
East Lansing, MI
Upon completion, participants should be able to:
- Describe factors driving opioid use disorders among veterans
- Describe strategies to screen appropriate patients for opioid use disorders
- Incorporate evidence-based resources provided by the VHA system and recent clinical data on emerging agents into the care of veterans with opioid use disorders
This activity is intended for physicians, nurses, pharmacists, and other clinicians in the federal healthcare system.
Series Overview/Statement of Need
Opioid abuse and misuse is one of the nation’s most pressing drug problems. Indeed, nearly one-half of all opioid overdose–related deaths are due to prescription opioids. Opioid use disorder (OUD) affects approximately 2 million adults in the United States, and as many as 1 in 4 persons receiving prescription opioids for chronic noncancer pain have developed an addiction. Mirroring trends in the general population, the use and abuse of opioids has also risen dramatically among the veteran population. OUD is a significant problem with substantial negative consequences on veterans’ physical and mental health, work performance, housing status, and social functioning. Alarmingly, veterans have twice the risk of unintentional opioid-related deaths compared with civilians. Thus, clinicians in the federal healthcare system must be familiar with factors driving opioid use among veterans, strategies to screen patients for OUD, and methods for incorporating evidence-based resources and recent clinical data into the care of veterans with this condition.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Med-IQ is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This nursing activity has been approved for up to 1.0 contact hour.
Med-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hour (0.1 CEU) of credit for pharmacists. ACPE #0476-0000-17-004-H01-P. This knowledge-based activity is designed for all pharmacists.
Other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This CME/CE/CPE activity consists of a 1.0-credit publication. To receive credit, read the introductory CME/CE/CPE material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 19, 2017
Expiration Date: December 18, 2018
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Thomas Kosten, MD
Consulting fees/advisory boards: Alkermes, Indivior Inc., Neurocrine Biosciences, Novartis Pharmaceuticals Corporation, Opiant Pharmaceuticals, Inc., Purdue Pharma L.P., US WorldMeds
Contracted research: Alkermes
Ownership interest (stocks/stock options – excluding mutual funds): Kadvax
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For CME-related questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer
Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Google Chrome - latest version
Apple Safari - latest version
Adobe Acrobat Reader® or Adobe Reader
Adobe Flash Player
Adobe Flash Player 9 or later
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: http://www.med-iq.com/privacy-statement/.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Indivior, Inc.
© 2017 Med-IQ, LLC
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.